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Abstract
Quantitative risk assessment (QRA) for food allergens has made considerable pro-
gress in recent years, yet acceptability of its outcomes remains stymied because of
the limited extent to which it has been possible to incorporate severity as a variable.
Reaction severity, particularly following accidental exposure, depends on multiple
factors, related to the allergen, the host and any treatments, which might be admin-
istered. Some of these factors are plausibly still unknown. Quantitative risk assess-
ment shows that limiting exposure through control of dose reduces the rates of
reactions in allergic populations, but its impact on the relative frequency of severe
reactions at different doses is unclear. Food challenge studies suggest that the
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however, the nonindustry members within
the expert group were offered support for
travel and accommodation costs from the
Food Allergy Task Force to attend meetings
to discuss the manuscript and a small
compensatory sum (honorarium) with the
option to decline. The expert group carried
out the work, that is collecting/analysing
data/information and writing the scientific
paper separate to other activities of the task
force. The research reported is the result of
a scientific evaluation in line with ILSI
Europe’s framework to provide a
precompetitive setting for public-private
partnership. ILSI Europe facilitated scientific
meetings and coordinated the overall project
relationship between dose of allergenic food and reaction severity is complex even
under relatively controlled conditions. Because of these complexities, epidemiologi-
cal studies provide very limited insight into this aspect of the dose-response rela-
tionship. Emerging data from single-dose challenges suggest that graded food
challenges may overestimate the rate of severe reactions. It may be necessary to
generate new data (such as those from single-dose challenges) to reliably identify
the effect of dose on severity for use in QRA. Success will reduce uncertainty in
the susceptible population and improve consumer choice.
K E YWORD S
allergenic foods, eliciting dose, precautionary allergen labelling, risk assessment, severity
management and administrative tasks
relating to the completion of this work. For
further information about ILSI Europe,
please email info@ilsieurope.be or call
+3227710014. The opinions expressed
herein and the conclusions of this
publication are those of the authors and do
not necessarily represent the views of ILSI
Europe nor those of its member companies
or any regulatory authority.
1 | INTRODUCTION
The unintended presence of food allergens, for instance due to cross-
contamination, is recognized as a food safety risk and has resulted in
the increasing use of precautionary allergen labelling (PAL) (eg, “may
contain X”). While the deliberate inclusion of 14 major common aller-
gens in food products is regulated through EU legislation,1 unintended
allergen presence is still handled only tangentially, particularly as
regards food safety legislation. Thus, food may be considered “unsafe”
if the information provided about it is inaccurate or misleading, or if it
is injurious to health, for example due to the “particular health sensitiv-
ities of a specific category of consumers”.2
What constitutes “injurious to health” to the allergic population
is not explicitly defined or quantified in legislation. For allergens, the
nature of any resulting reaction (of which severity is a critical com-
ponent) would seem a priori to be an important consideration. The
Food Allergen Labelling and Consumer Protection Act (2004)
(FALCPA) in the USA more explicitly enshrines the concept of an “al-
lergic response that causes a risk to human health,” which implies
that some reactions do not pose such a risk.
Approaches around the world differ in the assessment, manage-
ment and communication of the potential risk of unintended allergen
presence. Some authorities take a zero tolerance approach, where
any detectable allergen must be declared, while others use quantita-
tive benchmarks to inform such decisions. Much progress has been
made in characterizing the population distribution of minimum elicit-
ing doses (MEDs) triggering reactions in allergic individuals, for many
regulated food allergens. This has led to the concept of reference
doses to inform action levels or thresholds for allergen management
and, specifically, the need for PAL—ideally derived through the use
of quantitative risk assessment (QRA) models. For the first time,
these enable a measured estimate of the likelihood that a specific
exposure or dose will elicit a reaction. However, a number of evi-
dence gaps remain such as the lack of data on the relationship
between dose (amount) of allergen eaten and reaction severity. This
is a critical issue because severe reactions are of great concern, both
from the public health and the individual perspectives.3
In this paper, we discuss how dose affects reaction severity with
a particular focus on Paracelsus’s toxicological paradigm “the dose
makes the poison”4: specifically “does the proportion of severe reac-
tions increase with dose?” We also examine if the derivation of ref-
erence doses can be improved by including severity as a variable,
and whether this would enhance their value in risk assessment and
risk management.
2 | RISK AND RISK ASSESSMENT
Risk is defined as “[exposure to] the possibility of loss, injury, or
other adverse or unwelcome circumstance; a chance or situation
involving such a possibility” (Oxford English Dictionary). Risk is
ubiquitous in all aspects of life, and many entities, including the
International Organization for Standardization (ISO) and the
WHO-International Programme for Chemical Safety (WHO-IPCS),
have produced definitions specific to their own activities. All of
these definitions have in common the concept of risk as
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probability, associated with uncertainty about the outcome. The
concept of risk is wide-ranging, and any discussion must there-
fore carefully define the risk concept at issue to avoid confusion
and ambiguity.
2.1 | Risk and health outcomes
The risk to allergic consumers associated with allergenic foods is the
probability and nature of an adverse event (ie, an allergic reaction)
following exposure. This concept of risk clearly includes not only the
probability that an effect will be experienced, but also a considera-
tion of what that effect might be, that is, severity. In this context,
the most appropriate operational definition of risk is that proposed
by WHO-IPCS in Environmental Health Criteria 2405 as “a function
of the probability of an adverse health effect and the severity of that
effect, consequential to a hazard(s) in food.”
Assessment of the risk associated with allergenic foods, as
defined above, has been extensively discussed.6,7 In the approach
described, the hazard is characterized through modelling the popula-
tion dose distribution of MEDs obtained through double-blind, pla-
cebo-controlled food challenges (DBPCFCs).8,9 The generation of
these data from human studies is a strength, but the methodology
used for DBPCFC (where challenges are stopped at objective symp-
toms) limits our ability to characterize the effect of dose on reaction
severity. Better knowledge about the severity component and how it
varies with dose would provide great benefit, reducing uncertainty
among the susceptible population and giving them more choice
through the reduced need for PAL.
Figure 1 illustrates semiquantitatively the risks associated with
allergic reactions, characterized as type (as symptom severity) and
relative frequency of outcomes following allergen exposure, ranging
from no symptoms to life-threatening symptoms and finally to death,
a rare but unpredictable outcome. As discussed below, the percep-
tion of severity can differ significantly among stakeholders including
allergic individuals, their parents/carers, and healthcare professionals,
even for the same reactions.
2.2 | Dose control and management of cross-
contamination risk
A quantitative risk assessment process provides an estimate of the
probability that a specific population will experience allergic reac-
tions under defined conditions of exposure. The challenge of
defining management thresholds for a population where there is
high variation in individuals’ allergen thresholds has been described
elsewhere.6 However, risk managers from national food safety
authorities and the food industry need to interpret the outcome
of the risk assessment by reference to a defined concentration of
allergen, such as the action levels derived through the Voluntary
Incidental Trace Allergen Labelling (VITAL) system,10 to determine
exposure and risk at a population level. Consumption data add a
further variable that should reflect a normal food intake. Once the
management threshold level (action level) is determined for the
specific food product, with all associated uncertainties, it should
be compared to the actual levels determined by analytical meth-
ods to establish whether or not a product is “safe” for allergic
individuals.
Summary Section 2
• Risk assessment in food allergy includes both the probability of
experiencing an allergic reaction and the effect on health
reflected in reaction severity;
• Incorporating reaction severity into risk assessment and manage-
ment could reduce uncertainty in the susceptible population and
offer more consumer choice with less need for PAL.
3 | SEVERITY (SCORING) AND
STAKEHOLDER VIEWS
Severity is a relative term, which can be qualitatively categorized.
A moderate reaction is more “severe” than a mild reaction, but is
less “severe” than a severe reaction.3 International organizations
have put forward definitions of anaphylaxis. EAACI defines ana-
phylaxis as a “severe, potentially life-threatening systemic hyper-
sensitivity reaction”,11 and similarly, NIAID defines food-induced
anaphylaxis as: “a serious allergic reaction that is rapid in onset
and may cause death”.12 Some researchers have attempted to
quantify severity by reference to the number and nature of symp-
toms and have tried to account for influences other than dose of
allergen13 in a way that would allow objective comparison of care-
fully documented reactions. However, this approach has been con-
founded by the variable documentation of formal, guideline-based
or research-focused food challenges.14,15
3.1 | Perception of severity
Severity is a highly subjective term which stakeholders use and
interpret in different ways. Some symptoms may be visually severe
F IGURE 1 Hierarchy of risks faced by people susceptible to food
allergy
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(such as rash, facial swelling), without involving respiratory or car-
diovascular compromise. Others (eg impaired cognition, fluctuating
consciousness and subtle abnormalities in cardiac output) are
potentially life-threatening, but may not appear significant to non-
healthcare professionals or laypersons. Indeed, nonexpert clinicians
in ambulatory settings, lacking familiarity with the diversity of gen-
eralized allergic reactions, may also over- or underestimate reaction
severity.
Operationally, and for the purposes of deciding on acceptability,
it may be easier to define a nonsevere reaction: Such a reaction
would be self-limiting without treatment, would not interfere with
daily life activities and would be of short duration. This definition
overlaps with a suggested definition of “an allergic response that
poses a risk to human health” made in a US FDA public consultation
on thresholds.
Other perspectives on severity go beyond clinical symptoms and
their significance. Time off work, disruption of scheduled activity,
and direct and indirect economic loss may be judged more severe
consequences of an allergic reaction. Process failures in the food
chain may have “severe” reputational, economic or legal conse-
quences for companies perceived to be at fault, irrespective of clini-
cal impact.
Most allergists consider the fact that they do not usually see
their patients in the throes of an allergic reaction as a barrier to the
optimal use of severity data. Retrospective assessment of severity
can be difficult, but an allergy-focused clinical history looking for
reports or (even better) contemporaneous documentation of airway
or cardiovascular compromise (the quintessential features of “severe”
reactions) are the most useful clinical assessments.
3.2 | Acceptable risk and severity
Risk assessment provides a quantitative risk estimate, but ultimately
its purpose is to help define the acceptability or tolerability of a
specified risk, of which severity is a critical component.
During a workshop organized by ILSI Europe’s Food Allergy
Task Force in 2016, representatives of different stakeholder
groups, including those from the regulatory community, considered
the use of reference doses. All participants accepted that there
was a degree of risk associated with current approaches (and that
such risk is largely accepted). It was thought that using the ED10
(dose needed to elicit objective symptoms in 10% of the allergic
population) as likely to result in an unacceptable rate of severe
reactions in more sensitive allergic individuals. Further characteri-
zation of the nature of symptoms experienced by such individuals
reacting to an ED05 or ED01 was needed, to establish its
wider acceptability. Consumers might be prepared to tolerate
mild allergic symptoms if they were confident that such symp-
toms would be self-limiting. Participants noted that exposure to
allergens in amounts lower than the proposed ED01/05 level
is unlikely to elicit severe reactions, a position supported by
the results of a single-dose challenge study in peanut-allergic
individuals.16
3.3 | Communication of risks
Better information and education of patients and healthcare profes-
sionals about the consequences of exposure to defined low amounts
may help them understand the risks of using an ED01/05 level for
allergen risk management and make it more acceptable. Healthcare
professionals stressed the importance of a correct and proper diag-
nosis of food allergy and proposed that knowledge of an individual’s
MED, obtained from open food challenges or even from a single-
dose challenge, could also be valuable, even with its limitations. Indi-
viduals, including people with food allergies, differ in their accep-
tance of risk, ranging from risk-averse to risk-taking and even risk-
seeking.17 There is an urgent need to demystify food-induced aller-
gic reactions and provide education that not all reactions (or even
the majority) are anaphylaxis or life-threatening. Better communica-
tion with other stakeholders involved in assessing, managing or com-
municating allergen risks, and providing practical guidance on
allergen avoidance, was identified as a general need. Importantly,
any strategy utilizing reference doses must acknowledge the need to
provide appropriate support and education to those who may react
to levels of allergen exposure below the action levels.
Finally, labelling is an area where much needs to be done to
assure better understanding and therefore protection of allergic con-
sumers. Consumers and healthcare professionals alike are confused
as to the meaning and limitations of PAL. Information communicated
through allergen labelling needs to be as simple as possible, and sup-
ported by education and advice.
Summary Section 3
• Different stakeholders have different perspectives on what con-
stitutes a severe allergic reaction to foods;
• There is no universally accepted system for scoring the severity of
food-allergic reactions, but most clinicians would consider reactions
involving airway or cardiovascular compromise as severe;
• Despite the interpretative difficulties of differences in perception
and context, a consensus may be possible on what constitutes a
nonsevere reaction: namely, of short duration, self-limiting and
with no or limited impact on daily life activities;
• Severity is important in relation to acceptable risk, as the notion
of which allergic symptoms are acceptable is dependent on the
severity of such symptoms.
4 | FACTORS INFLUENCING THE SEVERITY
OF ALLERGIC REACTIONS
Fatal reactions are rare but also unpredictable. Turner et al3 recently
reviewed our ability (or inability) to reliably predict severity. Several
factors, acting together, are likely to contribute to the outcome of a
reaction and its severity (Figure 2):
• Allergen-related factors: The nature and circumstances of aller-
gen exposure are likely to impact upon reaction severity. Pea-
nut and tree nuts, seafood and cow’s milk are the most
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common causes of fatal food-induced anaphylaxis in the UK,
the USA and Australia.18-20 In contrast, soya appears less
likely to trigger severe reactions.18 The food matrix in which
the allergen is presented can affect severity: high fat (eg
chocolate) and heavily spiced foods may affect the kinetics of
allergen bioavailability, potentially delaying symptom onset,
minimizing initial mild oral symptoms and by confounding
“early warning signs” failing to limit the amount of allergen
consumed.21,22 Heat-processing can alter the structure of pro-
teins and therefore their recognition by specific immunoglobu-
lin E (sIgE) and, ultimately, the nature of any reaction.23 The
relationship between dose (exposure) and reaction severity is
less clear (see next section), although some (but not all) data
suggest that severe reactions to very low doses are uncom-
mon.24
• Host factors: These include factors which might affect the
ability of an allergen to stimulate a host effector cell response
(ie an allergic reaction) as well as factors which may modulate
the response. Perhaps the most studied factor is the level of
allergen-specific IgE, which, however, shows a poor correlation
with reaction severity (either historical, or that occurring at in-
hospital food challenge), as do “components” or IgE against
specific epitopes.3 “Extrinsic” factors (also referred to as
cofactors or augmentation factors) such as exercise, stress,
medication and alcohol can impact upon severity, as reviewed
elsewhere.3,25,26 Some individuals are also able to compensate
physiologically for an allergic reaction, to the extent of recov-
ering spontaneously from food-induced anaphylaxis.27 All these
complicate evaluation of the relationship between dose and
severity.
• Factors affecting reaction outcome: Severity, and the subse-
quent outcome, depend not only on the nature of the reaction,
but any subsequent intervention to control the reaction. Delays
in seeking medical attention and/or administration of adrenaline
(epinephrine) are common factors reported in fatal anaphylaxis.
Many severe reactions can have a good outcome if appropri-
ately treated with epinephrine. Contact or inhaled exposures
are less likely to trigger severe reactions. If dose affects the
rate of symptom progression, then a higher dose might limit
the time available to administer rescue medication. The ultimate
outcome of an allergic reaction expressed as a severity score
will thus require great care to integrate into a QRA. Smith
et al28 proposed the “Swiss cheese” model to illustrate how
these factors might interact to result in reactions of different
severity. Essentially, this approach postulates that a severe reac-
tion results from alignment of a whole set of circumstances,
of which ingested dose is only one factor, as illustrated in
Figure 2.
F IGURE 2 The “Swiss cheese” model. Adapted from reference28
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Summary Section 4
• Reaction severity is determined by multiple factors, related to
the allergen, the host and any treatments which might be
administered;
• These factors integrate in a multiplicity of ways to produce a
reaction of a certain severity, as illustrated by the “Swiss cheese”
model.
5 | CURRENT KNOWLEDGE ON THE
EFFECT OF DOSE ON SEVERITY OF FOOD-
ALLERGIC REACTIONS
Protection from severe reactions constitutes an important focus of
ensuring the safety of food-allergic consumers. In practice, this
means avoidance of the offending allergen, but how absolute that
avoidance must be remains a critical question. The interest in the
relationship between the level of exposure (dose) and the severity of
any resulting allergic reaction stems from the observation that of all
the parameters that may influence reaction severity, only dose can
be managed by the food industry.
Notwithstanding the potential importance of this, data describing
this relationship are scarce and often inadequate, particularly outside
controlled challenge studies. The available data can be found in epi-
demiological studies of populations, clinical case reports, and studies
using graded food challenges and are summarized in Table 1. A
recently introduced research tool is the single-dose food challenge,29
originally designed to validate reference doses derived from dose dis-
tribution models.
5.1 | Epidemiological and clinical case report data
The effect of dose on reaction severity has proved difficult to study.
Reasons include a lack of (precise) information about the presence,
quantity and bioavailability of the allergen ingested (precisely the vari-
able under study), as well as the relative contribution of factors other
than dose to the outcome. A community-based study where authors
estimated the ingested dose13 showed only a modest contribution to
reaction severity. Case series of (near) deaths have identified factors
associated with severe outcomes of accidental food-allergic reactions
in the community.30,31 These include adolescence/young adulthood,
concomitant asthma, peanut or tree nut or cow’s milk ingestion and
delayed treatment with adrenaline (epinephrine). However, given the
low incidence of fatal and near-fatal reactions to foods,32 the vast
majority of patients with these “high risk” characteristics will probably
never develop truly life-threatening reactions when exposed. It is diffi-
cult to determine the amounts consumed in fatal/severe reactions:
many severe reactions occur after relatively large doses of allergenic
food, but exceptions exist.33,34 Current data are thus inadequate to
describe the relationship between dose and severity, although while
the levels of exposure under these circumstances may be small in
absolute terms, they are typically many orders of magnitude greater
than any reference doses proposed for allergen management.
5.2 | Oral food challenge data
The “gold standard” for diagnosis of food allergy is a graded food
challenge; data generated by these procedures (relating to ED) have
been analysed to discern the relationship between severity and dose.
However, results have proved inconclusive.3,13 The principal reason
why challenge studies continue to be used in this way is that expo-
sure (ie dose of allergen) can be precisely defined. Further advan-
tages include direct, contemporaneous observations of reactions,
control of cofactors and (severity-modifying) medications. Despite
these benefits, this approach has important drawbacks. First, these
studies are principally aimed at identifying thresholds of reactivity
(MEDs) and the challenge is, with very few exceptions, stopped at
the first objective sign of a reaction. Other precautions taken to
TABLE 1 Selected studies assessing a potential relationship between dose and severity
Reference Type of study Statistical methods Dose and outcome Comments
13 Epidemiological,
community-based
and oral food challenge
Spearman’s rank correlation Weak association only Does not support the role of dose in
reaction severity
30 Case series of fatalities No formal statistical analysis
Frequencies and percentages
reported
No information on dose Study design cannot inform on role
of dose in severity
31 Case series of fatalities No formal statistical analysis
Frequencies and percentages
reported
No information on dose Study design cannot inform on role
of dose in severity
33 Case report None Not measured but probably low dose Study type cannot inform on role of
dose in severity
38 Oral food challenge Logistic regression Severe reactions at every dose Suggests no role of dose in severity,
but starting dose high relative to
reference doses
39 Oral food challenge Dose distribution modelling Higher MEDs associated with more
severe reactions
Seen only for peanut (not milk, egg
or soy) but excluded all mild reactors
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minimize the risk and limit reaction severity include (in some studies)
the exclusion of patients with recent severe reactions or severe and/
or unstable comorbidities; conducting challenges under baseline con-
ditions; and prompt and optimal treatment of reactions. It has been
suggested that giving incremental doses in succession may affect the
impact of subsequent doses, by inducing short-term oral tolerance;
this would underestimate the effect of any given dose, relative to
the same dose given in isolation.35 Conversely, reactions may be
triggered by the cumulative dose, rather than that given immediately
prior to reaction: confounding any attempt to relate severity to
dose.36 Finally, even reactions seen at food challenge are open to
considerable inter- and intra-observer variability.37
Analyses examining the relationship between MED and reaction
severity report that relatively severe reactions occur unpredictably
and at any dose.37,38 In order to quantify the effect of ED on reac-
tion severity, Pettersson et al (manuscript in preparation) analysed
data arising from 734 positive challenges at a single centre, using
multiple regression analysis to build a prediction model for challenge
reaction severity. This analysis showed that MED could only predict
4.4% of the variance of reaction severity (and all known factors
together, only 23.5% of total severity variance).
Zhu et al39 retrospectively classified the severity of MEDs from
graded food challenges performed at several centres and modelled
their distribution in the study population. For peanut, higher MEDs
were associated with more severe reactions, but no clear relation-
ship was discerned for milk, egg or soy. Importantly, Zhu et al were
unable to obtain and therefore include MEDs associated with mild
symptoms in their analysis: these constituted over 40% of the MEDs
in the source studies.39
Not all data from food challenges suggest that severe reactions
occur at any dose. Ballmer-Weber et al24 using a challenge protocol
where the initial dose was 0.003 mg protein, observed a clear absence
of severe symptoms to peanut, hazelnut, celery, fish and shrimp at
lower doses, and more frequent severe symptoms as doses increased.
This is in contrast to Rolinck-Werninghaus et al38 who, using an initial
dose of 3-5 mg protein (approximately an ED10 for the allergens
tested), reported severe reactions at all doses. The higher starting dose
may have obscured the relationship between dose and severity.
A recent re-analysis of challenge data by Wainstein & Turner,40
in which dose escalation continued despite the occurrence of mild
symptoms, reported three patterns of reaction: those whose first
symptom was anaphylaxis, a group with milder symptoms progress-
ing to anaphylaxis as the dose increased or treatment was delayed,
and finally a group who did not progress to anaphylaxis irrespective
of dose (see Figure 3). This suggests that a relationship between
dose and severity will not be readily apparent in individuals who
react with anaphylaxis as the initial objective symptom, depending
on starting dose. At a group or population level, the relationship
between dose and reaction severity may thus be obscured by the
heterogeneity of the tested allergic population.
5.3 | Single-dose challenges
Zurzolo et al29 introduced single-dose challenges to validate the EDs
calculated from population dose-distribution curves: a single dose
(corresponding to a specific ED value, for example ED05 for the
food in question, derived from a dose distribution curve) is given to
unselected individuals with the relevant allergy and the occurrence
and characteristics of any reactions recorded. In the only study pub-
lished to date, the ED05 for peanut was validated (1.5 mg peanut
protein), with 8 of 378 individuals meeting predetermined criteria for
a positive, objective reaction. No severe reactions occurred.16 Addi-
tional “single-dose” data can be found by studying historical food
challenge studies, where much higher starting doses were used. Two
F IGURE 3 Different patterns of clinical reactivity are seen at food challenge. Many individuals will experience initially subjective symptoms,
with objective symptoms appearing with further doses (A). Anaphylaxis will only develop if the food challenge continues. Others will
experience anaphylaxis as their first objective symptom: either at a dose of allergen exposure with no preceding subjective symptoms (B), or
with prior subjective symptoms (C). Note that anaphylaxis can occur at all levels of exposure (both at low levels of allergen exposure,
represented by the solid bars, and higher doses indicated by dotted lines). Reproduced (with permission) from reference40
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such studies (where initial doses were >200 mg protein) had a high
proportion (up to 30%) of severe symptoms among first dose reac-
tors.41,42 These imply that a quantifiable relationship does exist
between severity and dose. However, the circumstances leading to
relatively severe reactions at relatively low doses (3-5 mg protein) in
regular (multiple dose) food challenges remain unclear,38 and further
data from single-dose challenges are needed before definitive con-
clusions can be drawn. Again it must be stressed that the doses in
the Rolinck-Werninghaus study38 are at least 1.5 orders of magni-
tude higher than any amounts to which industry is seeking to man-
age the allergens tested.
Summary Section 5
• The only modifiable parameter, which may be controlled by pub-
lic health measures for food allergy, is exposure to the allergen,
that is dose;
• While limiting exposure is known to decrease the rates of reac-
tions in allergic populations, the impact of this on the relative fre-
quency of severe reactions at different doses is unclear;
• Reaction severity following accidental exposure depends on a
number of factors and variables, some of which are plausibly still
unknown. As a result, epidemiological studies provide very limited
insight into the dose-response relationship;
• Food challenge studies suggest that the relationship between
dose of allergenic food and reaction severity is complex and diffi-
cult to describe. Double-blind, placebo-controlled food challenges
may overestimate the severity of reactions at any given dose,
possibly because of cumulation of doses;
• Emerging data from single-dose challenges suggest that graded
food challenges may overestimate the rate of severe reactions.
6 | SEVERITY, DOSE AND QUANTITATIVE
RISK ASSESSMENT
Quantitative risk assessment models for food-allergic reactions have
been developed with probabilistic, Bayesian interfaces to estimate
the likelihood of eliciting a reaction to defined amounts of aller-
gen.43,44 Quantitative risk assessment requires quantitative descrip-
tion of any variable (including severity) and the associated
variability and uncertainty, which is currently hindered by the lack
of an agreed severity scoring scheme. Once operational, the QRA
would predict not only the number of reactions for any given dose
(as currently), but also the number of reactions at any given degree
of severity within the scoring scheme, which would define any
specified MED value. In risk management terms, this could translate
as a (management) threshold dose for severe reactions, which could
be set, for instance, as 1/10th of the threshold dose for severe
reactions.
While current probabilistic models do not include severity as a
variable, data are available that could already inform the severity
variables for risk assessment models. The proportion of severe reac-
tions at a given dose may be estimated for a number of foods from
studies, which include severity information (eg16,24,38,41,42). Any esti-
mate for proportion of severe reactions would need to be calculated
for each allergen (where sufficient data are available). Additional vari-
ables that modify severity (ie cofactors) could ultimately be added to
the QRA framework as more data become available.
Summary Section 6
• Probabilistic risk models may be improved if a quantitative
expression of severity could be extracted from clinical data;
• It may be necessary to generate new data (such as those from
single-dose challenges) in order to reliably identify the effect of
dose on severity for use in QRA.
7 | CONCLUSIONS AND
RECOMMENDATIONS
Quantitative analyses of data from controlled food challenges have
provided the basis for deriving benchmarks for allergen management.
New experimental approaches to the validation of these bench-
marks, such as the single-dose challenge, appear promising insofar as
they can also provide data on the characteristics of reactions at a
single dose, including reaction severity. However, such data are yet
to be integrated into and contribute to the outputs of current mod-
els, despite the value this would add from the perspective of public
health and risk assessment.
Concepts of risk vary among stakeholders, and different stake-
holders perceive severity in very different ways. Factors other than
dose may influence severity, both through their intrinsic importance
but also because they might dominate or mask the effect of dose.
The expert group concluded that these factors, whether related to
the allergen, the host or their effect on reaction outcome, play a
major role and often obscure the effect of dose.
Overall, the expert group concluded that data available on the
relationship between dose and severity are currently of insufficient
quality to be incorporated operationally into dose distribution mod-
elling approaches which describe the relationship between dose of
allergen and the proportion of the allergic population likely to react.
Consequently, the current focus should remain with efforts to base
benchmarks for allergen management (reference doses) on the latter
relationship, although the incorporation of severity parameters
should continue to be explored. The group noted that if the principal
public health goal is to minimize severe reactions, then reference
doses based on current data incorporate a “safety factor,” albeit one
that cannot currently be quantified. Additional work to understand
the impact of dose and other factors which determine severity will
be of value in order to better protect the allergic population and
ensure that measures taken to manage allergens are both effective
and proportionate. In the context of setting safe limits for allergen
management, for example for application of PAL, single-dose chal-
lenges can provide valuable information about the characteristics of
a reaction that might follow consumption of a product or meal on a
single occasion which unintentionally contained an allergen (eg by
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cross-contact) in an small amount not exceeding in total the dose
tested.
Developing a shared understanding among stakeholders of sever-
ity, and its implications for allergen risk assessment, may be as
important to the latter’s more general acceptance as refining the
underlying science. Communicating the issues discussed and conclu-
sions reached in this paper to healthcare professionals and people
with food allergies will be critical to developing this understanding,
and the expert group recognized the associated difficulties. Further
research into conveying risk messages through labelling is also
needed to ensure better understanding and therefore protection of
allergic consumers.
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